Logistic regression model of early discontinuation (n=757)
| Early discontinuation | Model I* | Model II† | ||||
| OR | P value | Adjusted OR | P value | Adjusted OR | P value | |
| (95% CI) | (95% CI) | (95% CI) | ||||
| Age group | 0.005 | 0.24 | 0.226 | |||
| <70 years | Reference | |||||
| ≥70 years | 2.39 (1.29 to 4.24) | 0.57 (0.22 to 1.44) | 0.56 (0.22 to 1.42) | |||
| Baseline CCI | <0.001 | 0.005 | 0.009 | |||
| 0–3 | Reference | |||||
| 4–7 | 4.21 (2.16 to 8.21) | <0.001 | 4.89 (1.88 to 12.75) | 0.001 | 4.38 (1.68 to 11.41) | 0.002 |
| ≥8 | 6.47 (0.57 to 72.58) | 0.13 | 3.76 (0.15 to 95.17) | 0.421 | 4.24 (0.15 to 11.78) | 0.394 |
| Parity | 0.003 | |||||
| 0 | Reference | |||||
| 1–2 | 0.86 (0.46 to 1.64) | 0.666 | ||||
| ≥3 | 2.47 (1.35 to 4.53) | 0.003 | ||||
| ECOG | <0.001 | |||||
| 0 | Reference | |||||
| 1 | 1.74 (0.97 to 3.09) | 0.059 | ||||
| 2 | 6.70 (3.11 to 14.46) | <0.001 | ||||
| Haemoglobin | 0.009 | |||||
| <10 | 2.35 (1.24 to 4.46) | |||||
| ≥10 | Reference | |||||
| Creatinine | 0.178 | |||||
| <1 | Reference | |||||
| ≥1 | 1.97 (0.73 to 5.29) | |||||
| CA125 | 0.371 | |||||
| <35 | Reference | |||||
| ≥35 | 1.48 (0.62 to 3.56) | |||||
| Type of surgery | <0.001 | <0.001 | <0.001 | |||
| Primary surgery | Reference | |||||
| Interval debulking | 0.61 (0.26 to 1.40) | 0.249 | 0.58 (0.25 to 1.35) | 0.027 | 0.41 (0.17 to 1.01) | 0.055 |
| No surgery | 22.48 (10.61 to 47.61) | <0.001 | 22.79 (10.03 to 51.77) | <0.001 | 15.38 (6.25 to 37.83) | <0.001 |
| Residual disease | 0.451 | |||||
| No residual disease | Reference | |||||
| Residual <1 cm | 1.07 (0.39 to 2.89) | 0.892 | ||||
| Residual ≥1 cm | 1.92 (0.86 to 4.31) | 0.11 | ||||
| Incomplete staging | 1.27 (0.50 to 3.21) | 0.613 | ||||
| Stage of disease | 0.002 | 0.261 | ||||
| I | Reference | |||||
| II | 1.36 (0.52 to 3.56) | 0.523 | 1.35 (0.51 to 3.59) | 0.544 | ||
| III | 2.86 (1.44 to 5.66) | 0.003 | 2.08 (0.95 to 4.52) | 0.065 | ||
| IV | 3.96 (1.73 to 9.07) | 0.001 | 2.33 (0.83 to 6.55) | 0.106 | ||
| Histology | 0.011 | |||||
| Endometrioid | Reference | |||||
| Serous | 0.94 (0.41 to 2.13) | 0.887 | ||||
| Clear cell | 1.10 (0.48 to 2.53) | 0.817 | ||||
| Mucinous | 1.14 (0.34 to 3.75) | 0.826 | ||||
| Others | 2.77 (1.30 to 5.92) | 0.008 | ||||
| Tumour grade | 0.64 | |||||
| 1 | Reference | |||||
| 2 | 1.00 (0.25 to 4.02) | 0.997 | ||||
| 3 | 1.41 (0.61 to 3.27) | 0.412 | ||||
| Chemotherapy | <0.001 | |||||
| Adjuvant | Reference | |||||
| Neoadjuvant and adjuvant | 0.48 (0.18 to 1.26) | 0.138 | ||||
| Neoadjuvant | 18.75 (9.58 to 36.70) | < 0.001 | ||||
| Regimen | 0.091 | |||||
| Combined platinum | Reference | |||||
| Single carboplatin | 1.78 (0.91 to 3.48) | |||||
*Model I: age group, baseline Charlson Comorbidity Index and type of surgery.
†Model II: age group, baseline Charlson Comorbidity Index, type of surgery and stage of disease.
CCI, Charlson Comorbidity Index; ECOG, Eastern Cooperative Oncology Group.